Research ArticleTuberculosis

Metformin as adjunct antituberculosis therapy

See allHide authors and affiliations

Science Translational Medicine  19 Nov 2014:
Vol. 6, Issue 263, pp. 263ra159
DOI: 10.1126/scitranslmed.3009885

eLetters is an online forum for ongoing peer review. Submission of eLetters are open to all. Please read our Terms of Service before submitting your own eLetter.

Compose eLetter

Plain text

  • Plain text
    No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g.
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

  • Tuberculostatic effect of metformin: Consider the elephant in the room

    Dear Editor,

    Singhal et al. demonstrate the inhibitory effect of metformin on growth of Mycobacterium tuberculosis (Mtb) in vitro and in vivo (1). We would like to draw attention to the potential role of the primary metabolite for which metformin is best known and prescribed, which is glucose itself. We believe metformin may affect growth of Mtb by restricting glucose availability.

    Glucose and infec...

    Show More
    Competing Interests: None declared.

Stay Connected to Science Translational Medicine